Vol. 6 (02) pp. 1496-1501 DOI: 10.21474/IJAR01/6581

CORONARY ARTERY DISEASE SUPERIMPOSED BY INTRACRANIAL HEMORRHAGE; HIGHLIGHTS AND MANAGEMENT.

, and
  • Al-Marefaa Colleges Of Science and Technology, Riyadh, Saudi Arabia.
  • Ibn Sina National College For Medical Studies, Jeddah, Saudi Arabia.
  • NationalHospital, Riyadh, Saudi Arabia.
8 Downloads 80 Views
Crossref

Download Full Paper (PDF)

Abstract

Coronary artery disease (CAD), is one of the major causes of death. It is a severe condition of stenosis of a major artery. Percutaneous intervention (PCI) is the common procedure that is done as the initial management of CAD. Dual antiplatelet prophylaxis is then given post PCI, for further prevention of cardiac events. This case report discusses then significance of CAD and management of intracranial hemorrhage (ICH) while of DAPT.

Article Analytics

References

  1. National Heart L, and Blood Institute. Coronary Heart Disease [Available from: https://www.nhlbi.nih.gov/health-topics/coronary-heart-disease.
  2. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, et al. Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25-146.
  3. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. 2017;135(10):e146-e603.
  4. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868-74.
  5. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111(25):3481-8.
  6. Steering Committee of the Physicians' Health Study Research G. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321(3):129-35.
  7. Dual Antiplatelet Therapy Acetylsalicylic Acid Dosing: A Review of the Clinical Effectiveness and Harms. 2017 Mar 14. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470792/.
  8. Task Force on Myocardial Revascularization of the European Society of C, the European Association for Cardio-Thoracic S, European Association for Percutaneous Cardiovascular I, Kolh P, Wijns W, Danchin N, et al. Guidelines on myocardial revascularization. Eur J Cardiothorac Surg. 2010;38 Suppl:S1-S52.
  9. Mehta SR, Tanguay JF, Eikelboom JW, Jolly SS, Joyner CD, Granger CB, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet. 2010;376(9748):1233-43.
  10. Hanna EB, Glancy DL, Saucedo JF. Antiplatelet and anticoagulant therapies in acute coronary syndromes. Cardiovasc Drugs Ther. 2010;24(1):61-70.
  11. Yaron Arbel M, a,b Maria C. Bennell, MSc,b Shaun G. Goodman, MD, MSc,c and, Harindra C. Wijeysundera M, PhDb,d,e. Cost-Effectiveness of Different Durations of Dual-Antiplatelet Use After Percutaneous Coronary Intervention. Canadian Journal of Cardiology. 2018;34(1):31-7.
  12. Valgimigli M, Campo G, Monti M, Vranckx P, Percoco G, Tumscitz C, et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125(16):2015-26.
  13. Palmerini T, Benedetto U, Bacchi-Reggiani L, Della Riva D, Biondi-Zoccai G, Feres F, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet. 2015;385(9985):2371-82.
  14. Navarese EP, Andreotti F, Schulze V, Kolodziejczak M, Buffon A, Brouwer M, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ. 2015;350:h1618.
  15. Savarese G, Savonitto S, Lund LH, Paolillo S, Marciano C, Dellegrottaglie S, et al. Efficacy and safety of prolonged dual antiplatelet therapy: a meta-analysis of 15 randomized trials enrolling 85 265 patients. Eur Heart J Cardiovasc Pharmacother. 2016;2(4):218-28.
  16. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706-17.
  17. Wilson SJ, Newby DE, Dawson D, Irving J, Berry C. Duration of dual antiplatelet therapy in acute coronary syndrome. Heart. 2017;103(8):573-80.
  18. Gandhi S, Zile B, Tan MK, Saranu J, Bucci C, Yan AT, et al. Increased uptake of guideline-recommended oral antiplatelet therapy: insights from the Canadian acute coronary syndrome reflective. Can J Cardiol. 2014;30(12):1725-31.
  19. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-57.
  20. Clemmensen P, Dridi NP, Holmvang L. Dual antiplatelet therapy with prasugrel or ticagrelor versus clopidogrel in interventional cardiology. Cardiovasc Drugs Ther. 2013;27(3):239-45.
  21. Testa L, Biondi Zoccai GG, Valgimigli M, Latini RA, Pizzocri S, Lanotte S, et al. Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents. Adv Hematol. 2010;2010:595934.
  22. Schuler J, Maier B, Behrens S, Thimme W. Present treatment of acute myocardial infarction in patients over 75 years--data from the Berlin Myocardial Infarction Registry (BHIR). Clin Res Cardiol. 2006;95(7):360-7.
  23. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009;373(9665):723-31.
  24. Hemphill JC, 3rd, Greenberg SM, Anderson CS, Becker K, Bendok BR, Cushman M, et al. Guidelines for the Management of Spontaneous Intracerebral Hemorrhage: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2015;46(7):2032-60.
  25. Zahuranec DB, Gonzales NR, Brown DL, Lisabeth LD, Longwell PJ, Eden SV, et al. Presentation of intracerebral haemorrhage in a community. J Neurol Neurosurg Psychiatry. 2006;77(3):340-4.
  26. Broderick JP, Adams HP, Jr., Barsan W, Feinberg W, Feldmann E, Grotta J, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke. 1999;30(4):905-15.
  27. Nadeem I. Khan MFMS, MD; Joshua N. Goldstein, MD, PhD; Margueritte Cox, MS; Ying Xian, MD, PhD; Roland A. Matsouaka, PhD; Paul A. Heidenreich, MD, MS; Eric D. Peterson, MD, MPH; Deepak L. Bhatt, MD, MPH; Gregg C. Fonarow, MD; Lee H. Schwamm, MD; Eric E. Smith, MD, MPH. Association Between Previous Use of Antiplatelet Therapy and Intracerebral Hemorrhage Outcomes. http://strokeahajournalsorg/. Stroke. 2017.
  28. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998;280(22):1930-5.
  29. Ducrocq G, Amarenco P, Labreuche J, Alberts MJ, Mas JL, Ohman EM, et al. A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease. Circulation. 2013;127(6):730-8.
  30. Serebruany VL, Malinin AI, Eisert RM, Sane DC. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol. 2004;75(1):40-7.
  31. Lee M SJ, Hong KS, Rao NM, Wu YL, Ovbiagele B. Risk benefit profile of long-term dual versus single antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. . Ann Intern Med. 2013;159:463?470.
  32. Chen S SQ, Tang Y, He L, Li Y, Li H, et al. Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials. 2014;9:e104402.
  33. Naik BI, Keeley EC, Gress DR, Zuo Z. Case scenario: a patient on dual antiplatelet therapy with an intracranial hemorrhage after percutaneous coronary intervention. Anesthesiology. 2014;121(3):644-53.
  34. Nishijima DK ZS, Berrong J, Legome E. . Utility of platelet tranfusion in adult patients with traumatic intracranial hemorrhage and preinjury antiplatelet use: a systematic review. Trauma Acute Care Surg 2012;72:1658-63.
  35. Naidech AM LS, Rosenberg NF, Lindholm PF, Bernstein RA, Batjer HH, Alberts MJ, Kwaan HC. . Early Platelet Transfusion Improves Platelet Activity and May Improve Outcomes After Intracerebral Hemorrhage. Neurotic care 2012;16:82-7.
  36. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58(24):e44-122.

How to Cite This Article

Abdulaziz S. Al-Humoud, Aseel H. Askar and Ali S. Al-Masoud. (2018); CORONARY ARTERY DISEASE SUPERIMPOSED BY INTRACRANIAL HEMORRHAGE; HIGHLIGHTS AND MANAGEMENT., Int. J. of Adv. Res., 6 (02), 1496-1501, ISSN 2320-5407. DOI: https://doi.org/10.21474/IJAR01/6581

Corresponding Author

Abdulaziz S. Al-Humoud
Al-Marefaa Colleges
Creative Commons Attribution 4.0 This work is licensed under a Creative Commons Attribution 4.0 International License.